These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 3836544)

  • 1. [In vitro effect of 2 pharmaceutical preparations containing bismuth on the fermentative capacity of intestinal bacteria].
    León-Barúa R; Tello-Casanova R
    Acta Gastroenterol Latinoam; 1985; 15(3):157-64. PubMed ID: 3836544
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [The high fermentative capacity of colonic bacteria in the origin of flatulence and its sensibility to bismuth subsalicylate].
    León-Barúa R; Alvarez De Roig M; Roig-Arosemena J; Berendson-Seminario R; Torres-Zevallos H
    Rev Gastroenterol Peru; 2007; 27(1):21-4. PubMed ID: 17431432
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro and in vivo effects of three bismuth compounds on fermentation by colonic bacteria.
    León-Barúa R; Tello R; Morante MC; Alvarez M; Gilman RH; Spira WM
    Rev Infect Dis; 1990; 12 Suppl 1():S24-9. PubMed ID: 2305175
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [In vitro effect of 10 antimicrobial agents on the fermentative capacity of the intestinal bacteria].
    Morante-Bedoya MC; León-Barúa R
    Acta Gastroenterol Latinoam; 1987; 16(4):249-60. PubMed ID: 3425173
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Mucin: a probable endogenous substrate of intestinal fermentation].
    Barúa RL; Tello Casanova R
    Acta Gastroenterol Latinoam; 1984; 14(4):279-83. PubMed ID: 6537703
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Control of fecal fermentation with paramomycin and metronidazole].
    León-Barúa R; Tello-Casanova R
    Arq Gastroenterol; 1982; 19(3):120-6. PubMed ID: 7185361
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reduced tetracycline bioavailability caused by magnesium aluminum silicate in liquid formulations of bismuth subsalicylate.
    Healy DP; Dansereau RJ; Dunn AB; Clendening CE; Mounts AW; Deepe GS
    Ann Pharmacother; 1997 Dec; 31(12):1460-4. PubMed ID: 9416381
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evidence that bismuth salts reduce invasion of epithelial cells by enteroinvasive bacteria.
    Gump DW; Nadeau OW; Hendricks GM; Meyer DH
    Med Microbiol Immunol; 1992; 181(3):131-43. PubMed ID: 1522823
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro bile acid adsorption by bismuth subsalicylate and montmorillonite.
    Kocoshis SA; Ghent CN; Gryboski JD
    Dig Dis Sci; 1984 Dec; 29(12):1148-52. PubMed ID: 6499633
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative absorption of bismuth in Sprague-Dawley rats following oral administration of preparations containing bismuth sucrose octasulfate, bismuth subsalicylate, and bismuth subcitrate.
    Rao N; Brown PW; Yerino P; Chang J; Hwang KK
    Biopharm Drug Dispos; 1997 Jan; 18(1):1-8. PubMed ID: 9008264
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Basal fecal fermentation and with lactulose in patients with flatulence].
    Wong-Alcázar CE; León R; de Roig MA; Roig-Arosemena J; Berendson-Seminario R; Biber-Poillevard M
    Rev Gastroenterol Peru; 2004; 24(2):123-6. PubMed ID: 15241490
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Influence of subsalicylate bismuth on absorption of doxycycline.
    Ericsson CD; Feldman S; Pickering LK; Cleary TG
    JAMA; 1982 Apr; 247(16):2266-7. PubMed ID: 7040708
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influence of source and concentrations of dietary fiber on in vivo nitrogen excretion pathways in pigs as reflected by in vitro fermentation and nitrogen incorporation by fecal bacteria.
    Bindelle J; Buldgen A; Delacollette M; Wavreille J; Agneessens R; Destain JP; Leterme P
    J Anim Sci; 2009 Feb; 87(2):583-93. PubMed ID: 18791157
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The use of bismuth tripotassium dicitrate (De-Nol), a promising line of pathogenetic therapy for irritated bowel syndrome with diarrhea].
    Iakovenko EP; Agafonova NA; Pokhal'skaia OIu; Kolganova AV; Nazarbekova RS; Ivanov AN; Davletshina IV; Popova EV; Prianishnikova AS; Ovchinnikova NI; Iakovenko AV; Aldiiarova MA; D'iachkoava AV; Gioeva IZ
    Klin Med (Mosk); 2008; 86(10):47-52. PubMed ID: 19069460
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Absorption of salicylate and bismuth from a bismuth subsalicylate--containing compound (Pepto-Bismol).
    Pickering LK; Feldman S; Ericsson CD; Cleary TG
    J Pediatr; 1981 Oct; 99(4):654-6. PubMed ID: 7277115
    [No Abstract]   [Full Text] [Related]  

  • 16. Bismuth subsalicylate: history, chemistry, and safety.
    Bierer DW
    Rev Infect Dis; 1990; 12 Suppl 1():S3-8. PubMed ID: 2406853
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interaction of bismuth subsalicylate with fruit juices, ascorbic acid, and thiol-containing substrates to produce soluble bismuth products active against Clostridium difficile.
    Mahony DE; Woods A; Eelman MD; Burford N; Veldhuyzen van Zanten SJ
    Antimicrob Agents Chemother; 2005 Jan; 49(1):431-3. PubMed ID: 15616328
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of bismuth subsalicylate on ciprofloxacin bioavailability.
    Rambout L; Sahai J; Gallicano K; Oliveras L; Garber G
    Antimicrob Agents Chemother; 1994 Sep; 38(9):2187-90. PubMed ID: 7811043
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Salicylate in Pepto-Bismol.
    Med Lett Drugs Ther; 1980 Jul; 22(15):63. PubMed ID: 7393125
    [No Abstract]   [Full Text] [Related]  

  • 20. The absorption of bismuth and salicylate from oral doses of Pepto-Bismol (bismuth salicylate).
    Nwokolo CU; Mistry P; Pounder RE
    Aliment Pharmacol Ther; 1990 Apr; 4(2):163-9. PubMed ID: 2104082
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.